德琪医药-B(06996)股东将股票由渣打银行(香港)转入高盛(亚洲)证券 转仓市值4.82亿港元

Core Insights - The stock of Deking Pharmaceutical-B (06996) was transferred from Standard Chartered Bank (Hong Kong) to Goldman Sachs (Asia) Securities on August 19, with a market value of HKD 482 million, representing 9.74% of the total shares [1] Company Developments - Deking Pharmaceutical-B announced that its internally developed Claudin 18.2 antibody-drug conjugate (ADC) ATG-022 has received breakthrough therapy designation from the National Medical Products Administration (NMPA) in China for the treatment of patients with CLDN18.2 positive, HER2 negative unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma who have previously received at least two treatments [1]